靶向肠道微生物治疗肝病的研究进展  

Research progress in the treatment of liver disease by targeting intestinal microbes

作　　者：拜刘辉 闫向东 齐平 吕金 张磊[1,2] Bai Liuhui;Yan Xiangdong;Qi Ping;Lyu Jin;Zhang Lei(The First Clinical Medical School,Lanzhou University,Lanzhou 730000,China;Department of General Surgery,The First Hospital of Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学第一临床医学院,甘肃兰州730000 [2]兰州大学第一医院普外科,甘肃兰州730000

出　　处：《兰州大学学报（医学版）》2023年第12期82-87,共6页Journal of Lanzhou University（Medical Sciences）

基　　金：国家自然科学基金资助项目(31960236);兰州市人才创新创业资助项目(2019-RC-34);甘肃省自然科学基金资助项目(21JR7RA369);兰州市城关区科技规划资助项目(2020SHFZ0029);兰州大学第一医院基金资助项目(ldyyyn2019-75)

摘　　要：肠道微生物参与多种肝病的发生和发展,如病毒性肝炎、酒精肝、脂肪肝和肝癌等。肠-肝轴作为联系肝和肠道的重要通道,扮演不可或缺的角色。肝病患者体内肠道微生物比例失调,通过抗生素、益生菌等靶向调节肠-肝轴中的微生物群,延缓疾病进展、降低死亡率,有重要的临床意义。本文对靶向调节肠道微生物群治疗肝病的相关研究进行综述。Gut microbiota are involved in the occurrence and development of a variety of liver diseases,such as viral hepatitis,alcoholic liver,fatty liver and liver cancer.As an important channel connecting the liver and intestine,the gut-liver axis plays an indispensable role.Patients with liver diseases have a dysregulated proportion of intestinal microbes.It is of great clinical significance to treat these diseases by targeting the microbiota in the gut-liver axis with antibiotics and probiotics to delay disease progression and reduce mortality.For this purpose,this article reviewed research on targeted regulation of gut microbiota in the treat-ment of liver diseases.

关 键 词：微生物群 肠-肝轴 靶向治疗 肝病 肝肠循环 胆汁酸代谢 

分 类 号：Q939.93[生物学—微生物学] R735.7[医药卫生—肿瘤]